Patent: 9,839,579
✉ Email this page to a colleague
Summary for Patent: 9,839,579
| Title: | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| Abstract: | The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, Victoza (liraglutide), Tresiba (insulin degludec), Ryzodeg (insulin degludec/insulin aspart), IDegLira (liraglutide and insulin degludec), NovoSeven (recombinant human coagulation factor VIIa), NovoSeven RT (recombinant human coagulation factor VIIa), or Turoctocog alfa (third-generation recombinant coagulation factor VIII). |
| Inventor(s): | Weeks; Wendell P. (Corning, NY), Schaut; Robert Anthony (Painted Post, NY), DeMartino; Steven Edward (Painted Post, NY), Peanasky; John Stephen (Big Flats, NY) |
| Assignee: | Corning Incorporated (Corning, NY) |
| Application Number: | 14/259,277 |
| Patent Claims: | see list of patent claims |
Details for Patent 9,839,579
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Novo Nordisk Inc. | NOVOLOG | insulin aspart | Injection | 020986 | 06/07/2000 | ⤷ Try a Trial | 2033-04-24 |
| Novo Nordisk Inc. | NOVOLOG | insulin aspart | Injection | 020986 | 01/19/2001 | ⤷ Try a Trial | 2033-04-24 |
| Novo Nordisk Inc. | NOVOLOG | insulin aspart | Injection | 020986 | 04/23/2004 | ⤷ Try a Trial | 2033-04-24 |
| Novo Nordisk Inc. | NOVOLOG | insulin aspart | Injection | 020986 | 10/31/2013 | ⤷ Try a Trial | 2033-04-24 |
| Novo Nordisk Inc. | NOVOSEVEN, NOVOSEVEN RT | coagulation factor viia (recombinant) | For Injection | 103665 | 03/25/1999 | ⤷ Try a Trial | 2033-04-24 |
| Novo Nordisk Inc. | NOVOSEVEN, NOVOSEVEN RT | coagulation factor viia (recombinant) | For Injection | 103665 | 11/15/2000 | ⤷ Try a Trial | 2033-04-24 |
| Novo Nordisk Inc. | NOVOSEVEN, NOVOSEVEN RT | coagulation factor viia (recombinant) | For Injection | 103665 | 05/09/2008 | ⤷ Try a Trial | 2033-04-24 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
